In line, patient-derived xenograft models of NPM1-mutated AML showed promising results with the menin inhibitor VTP5046940 and first data of a subsequent phase I study demonstrated single agent activity also in patients with NPM1-mutated AML41. This evidence concerns the gene MEN1 and acute myeloid leukemia.